{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=GLP-1&page=11",
    "query": {
      "intervention": "GLP-1",
      "page": 11
    },
    "page_size": 10
  },
  "pagination": {
    "page": 11,
    "page_size": 10,
    "total_count": 804,
    "total_pages": 81,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=GLP-1&page=12&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=GLP-1&page=10&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-19T01:12:04.776Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01658501",
      "title": "Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "50 mg PB1023",
          "type": "DRUG"
        },
        {
          "name": "70 mg PB1023",
          "type": "DRUG"
        },
        {
          "name": "100 mg PB1023",
          "type": "DRUG"
        },
        {
          "name": "Placebo (0.9% Sodium Chloride)",
          "type": "DRUG"
        },
        {
          "name": "Victoza®",
          "type": "DRUG"
        },
        {
          "name": "Diet and Exercise",
          "type": "OTHER"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        },
        {
          "name": "Sulfonylurea",
          "type": "DRUG"
        },
        {
          "name": "Metformin and Sulfonylurea",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "PhaseBio Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 593,
      "start_date": "2012-07",
      "completion_date": "2013-07",
      "has_results": false,
      "last_update_posted_date": "2015-12-07",
      "last_synced_at": "2026-10-19T01:12:04.776Z",
      "location_count": 93,
      "location_summary": "Anniston, Alabama • Birmingham, Alabama • Gulf Shores, Alabama + 90 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gulf Shores",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01658501"
    },
    {
      "nct_id": "NCT07736729",
      "title": "Continuous Wearable Biometric Monitoring in Adults Undergoing Obesity Treatment (SMART-BMI)",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Biometric-informed care",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Control Arm: Standard Care",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Jeff Reeves",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 260,
      "start_date": "2026-08-17",
      "completion_date": "2031-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-07-30",
      "last_synced_at": "2026-10-19T01:12:04.776Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07736729"
    },
    {
      "nct_id": "NCT03439072",
      "title": "G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Insulin Hypoglycemia",
        "Type 1 Diabetes Mellitus",
        "Severe Hypoglycemia"
      ],
      "interventions": [
        {
          "name": "G-Pen",
          "type": "DRUG"
        },
        {
          "name": "Lilly Glucagon",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Xeris Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 81,
      "start_date": "2018-01-23",
      "completion_date": "2018-05-03",
      "has_results": true,
      "last_update_posted_date": "2020-02-17",
      "last_synced_at": "2026-10-19T01:12:04.776Z",
      "location_count": 4,
      "location_summary": "Chula Vista, California • Walnut Creek, California • Atlanta, Georgia + 1 more",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Renton",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03439072"
    },
    {
      "nct_id": "NCT00207389",
      "title": "A Study to Examine Changes in GIP Plasma Levels Following Gastric Bypass Surgery in Obese Patients",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Obesity",
        "Type 2 Diabetes Mellitus",
        "Insulin Resistance"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Boston Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "21 Years to 64 Years"
      },
      "enrollment_count": 5,
      "start_date": "2004-03",
      "completion_date": "2006-08",
      "has_results": false,
      "last_update_posted_date": "2017-01-26",
      "last_synced_at": "2026-10-19T01:12:04.776Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00207389"
    },
    {
      "nct_id": "NCT04172441",
      "title": "Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Congenital Hyperinsulinism"
      ],
      "interventions": [
        {
          "name": "dasiglucagon",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Zealand Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Days",
        "maximum_age": "364 Days",
        "sex": "ALL",
        "summary": "7 Days to 364 Days"
      },
      "enrollment_count": 12,
      "start_date": "2020-06-19",
      "completion_date": "2022-03-07",
      "has_results": true,
      "last_update_posted_date": "2025-03-14",
      "last_synced_at": "2026-10-19T01:12:04.776Z",
      "location_count": 2,
      "location_summary": "Philadelphia, Pennsylvania • Fort Worth, Texas",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04172441"
    },
    {
      "nct_id": "NCT06500429",
      "title": "A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) Agonist",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Overweight and Obesity",
        "Healthy"
      ],
      "interventions": [
        {
          "name": "NG101",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Semaglutide Injectable Product",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neurogastrx, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 120,
      "start_date": "2024-06-24",
      "completion_date": "2024-09-13",
      "has_results": false,
      "last_update_posted_date": "2025-09-04",
      "last_synced_at": "2026-10-19T01:12:04.776Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06500429"
    },
    {
      "nct_id": "NCT02518945",
      "title": "Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Insulin",
          "type": "DRUG"
        },
        {
          "name": "Liraglutide",
          "type": "DRUG"
        },
        {
          "name": "Dapagliflozin placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University at Buffalo",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 26,
      "start_date": "2015-08",
      "completion_date": "2016-04",
      "has_results": true,
      "last_update_posted_date": "2024-01-24",
      "last_synced_at": "2026-10-19T01:12:04.776Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02518945"
    },
    {
      "nct_id": "NCT03415139",
      "title": "Finding the Cause for Post-Transplant Diabetes Mellitus After Allogeneic Hematopoietic Cell Transplant",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diabetes Mellitus",
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Oral Glucose Tolerance Test (OGTT)",
          "type": "DRUG"
        },
        {
          "name": "2 OGTTs with and without GLP-1 analogue",
          "type": "DRUG"
        },
        {
          "name": "Hyperglycemic clamp procedure",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt-Ingram Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 120,
      "start_date": "2019-03-12",
      "completion_date": "2025-04",
      "has_results": false,
      "last_update_posted_date": "2022-03-28",
      "last_synced_at": "2026-10-19T01:12:04.776Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03415139"
    },
    {
      "nct_id": "NCT04775082",
      "title": "SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Liraglutide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "6 Years to 12 Years"
      },
      "enrollment_count": 78,
      "start_date": "2021-03-04",
      "completion_date": "2027-02-08",
      "has_results": false,
      "last_update_posted_date": "2026-07-09",
      "last_synced_at": "2026-10-19T01:12:04.776Z",
      "location_count": 9,
      "location_summary": "Tucson, Arizona • Denver, Colorado • Meridian, Idaho + 6 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Meridian",
          "state": "Idaho"
        },
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04775082"
    },
    {
      "nct_id": "NCT01671579",
      "title": "Comparison of Bowel Ultrasound & MR Enterography in the Follow-up of Previously Diagnosed Pediatric Small Bowel Crohn Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Crohn Disease"
      ],
      "interventions": [
        {
          "name": "Bowel ultrasound",
          "type": "PROCEDURE"
        },
        {
          "name": "magnetic resonance enterography (MRE)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Children's Hospital Medical Center, Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "10 Years to 18 Years"
      },
      "enrollment_count": 33,
      "start_date": "2012-03",
      "completion_date": "2017-08",
      "has_results": false,
      "last_update_posted_date": "2018-01-25",
      "last_synced_at": "2026-10-19T01:12:04.776Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01671579"
    }
  ]
}